Found: 14
Select item for more details and to access through your institution.
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.
- Published in:
- Nature Medicine, 2010, v. 16, n. 4, p. 483, doi. 10.1038/nm.2112
- By:
- Publication type:
- Article
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma.
- Published in:
- British Journal of Haematology, 2018, v. 182, n. 2, p. 222, doi. 10.1111/bjh.15261
- By:
- Publication type:
- Article
Patient‐reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double‐blind, placebo‐controlled PANORAMA‐1 trial.
- Published in:
- British Journal of Haematology, 2018, v. 181, n. 5, p. 628, doi. 10.1111/bjh.15248
- By:
- Publication type:
- Article
Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.
- Published in:
- British Journal of Haematology, 2017, v. 179, n. 1, p. 66, doi. 10.1111/bjh.14821
- By:
- Publication type:
- Article
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.
- Published in:
- British Journal of Haematology, 2014, v. 166, n. 3, p. 401, doi. 10.1111/bjh.12909
- By:
- Publication type:
- Article
Emerging Treatment Options in the Management of Multiple Myeloma.
- Published in:
- Journal of Managed Care Medicine, 2013, v. 16, n. 1, p. 25
- By:
- Publication type:
- Article
MGUS and Smoldering Myeloma: the Most Prevalent of Plasma Cell Dyscrasias.
- Published in:
- Oncology (08909091), 2011, v. 25, n. 7, p. 594
- By:
- Publication type:
- Article
Tailoring Treatment for Multiple Myeloma Patients With Relapsed and Refractory Disease.
- Published in:
- Oncology (08909091), 2010, v. 24, n. 3, p. 22
- By:
- Publication type:
- Article
Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays.
- Published in:
- Oncogene, 2002, v. 21, n. 9, p. 1346, doi. 10.1038/sj.onc.1205205
- By:
- Publication type:
- Article
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
- Published in:
- European Journal of Haematology, 2012, v. 88, n. 5, p. 446, doi. 10.1111/j.1600-0609.2012.01765.x
- By:
- Publication type:
- Article
The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.
- Published in:
- European Journal of Haematology, 2012, v. 88, n. 1, p. 1, doi. 10.1111/j.1600-0609.2011.01721.x
- By:
- Publication type:
- Article
A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.
- Published in:
- American Journal of Hematology, 2011, v. 86, n. 7, p. 573, doi. 10.1002/ajh.22048
- By:
- Publication type:
- Article
research paper Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.
- Published in:
- British Journal of Haematology, 2004, v. 125, n. 3, p. 343, doi. 10.1111/j.1365-2141.2004.04929.x
- By:
- Publication type:
- Article
Viral antigen-specific CD8<sup>+</sup> T-cell responses are impaired in multiple myeloma.
- Published in:
- British Journal of Haematology, 2003, v. 121, n. 6, p. 842, doi. 10.1046/j.1365-2141.2003.04375.x
- By:
- Publication type:
- Article